Comparing the current results to its competitors, Acadia Pharmaceuticals Inc reported Revenue increase in the 1 quarter 2026 by 9.72 % year on year. The revenue growth was below Acadia Pharmaceuticals Inc 's competitors' average revenue growth of 26.74 %, achieved in the same quarter.
Acadia Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes pharmaceutical and biotechnology firms, academic and research institutions, and governmental agencies worldwide. Its product NUPLAZID, indicated for the treatment of Parkinson's disease psychosis (PDP), competes with the off-label use of antipsychotic drugs such as quetiapine, clozapine, risperidone, aripiprazole, and olanzapine. The company's product DAYBUE competes indirectly with the off-label use of branded and generic medications for Rett syndrome symptoms, including antiepileptics, antipsychotics, antidepressants, and benzodiazepines. Other pharmaceutical companies are developing or may develop pipeline or marketed products for Rett syndrome, and some competitors may have drugs in development or pending regulatory approval that could reach the market before the company's products. Additionally, competitors may develop alternative therapies that could reduce the market potential for the company's drugs.
December 12, 2024
Acadia Pharmaceuticals Concludes $150 Million Sale of Rare Pediatric Disease Priority Review Voucher SAN DIEGO Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced the successful closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for an impressive $150 million before fees and expenses. This landmark financial transaction, executed in line with a definitive asset purchase agreement, came to fruition following a prior announcement made on November 5, 2024.The PRV, which the U.S. Food and Drug Administration (FDA) granted to Acadia in March 2023, was a key milestone following the approval of DAYBUE (trofinetide) for the treatment of Rett syndrome. This novel treatment, aimed at ...
May 18, 2024
Acadia Pharmaceuticals: Monumental Strides in Employee Inducement, Financial Growth, and Drug Development SAN DIEGO Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) continues to make waves in the biopharmaceutical sector, marked by significant developments across its operational strategy, financial performance, and innovative drug development efforts.On May 15, 2024, the Compensation Committee of Acadia’s Board of Directors granted inducement awards to twenty-two new employees, reflecting the company s commitment to attracting top-tier talent. These awards, approved under Acadia s 2023 Inducement Plan, comprise non-qualified stock options to purchase 57,252 shares of common stock, alongside 33,675 restricted...
April 22, 2024
Acadia Pharmaceuticals Trofinetide Receives Priority Review for Rett Syndrome Treatment in CanadaAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) has recently announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide, a potential treatment for Rett syndrome, a rare and complex neurodevelopmental disorder. This comes as a significant development for patients and families affected by this debilitating condition.Rett syndrome is a challenging disorder that manifests differently in each individual, making it difficult to predict symptoms or their severity. People with Rett syndrome often experience severe cognitive and physical impairments, including loss of purposeful hand skills, speec...
Publicly Traded Peers of Acadia Pharmaceuticals Inc
Inmed Pharmaceuticals Inc Share Performance
-13.21%
This Quarter
Inmed Pharmaceuticals Inc
Profile
Inmed Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of cannabinoid-based therapies for various diseases. The company's business model revolves around conducting research and development to identify novel drug candidates, conducting pre-clinical and clinical trials to test the safety and efficacy of these candidates, and seeking partnerships or collaborations with other pharmaceutical companies for the further development and commercialization of successful therapies. By leveraging advancements in cannabinoid science, Inmed Pharmaceuticals aims to provide innovative medical treatments for unmet medical needs.
Neurocrine Biosciences Inc's business model involves researching, developing, and commercializing innovative therapies for neurological and endocrine disorders.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Sources:
Acadia Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Acadia Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
